Exicure Inc Dossier - Source-backed chat

Exicure Inc

XCURNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)2.75

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.18Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $7.7M

Enterprise Value $3.3M

Shares Outstanding 6.4M diluted

Next Earnings Date16 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Exicure, Inc. (XCUR) is in a state of severe financial distress, characterized by a going concern warning, zero revenue, and acute liquidity constraints. While the company successfully pivoted its clinical focus to hematology through the acquisition of GPCR Therapeutics USA and its lead asset Burixafor (GPC-100), its balance sheet is highly fragile with only $2.6 million in cash as of March 31, 2026. Furthermore, Exicure is out of compliance with Nasdaq's minimum stockholders' equity requirement. Despite promising Phase 2 data for Burixafor in stem cell mobilization and a co-development agreement with Adbiotech, the high risk of near-term dilutive financing, execution hurdles, and potential delisting make the stock an exceptionally high-risk vehicle, justifying a Strong Sell recommendation for risk-averse investors.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The company fails to raise necessary capital or resolve its Nasdaq stockholders' equity deficiency, leading to delisting from the Nasdaq Capital Market. Clinical development of Burixafor is suspended indefinitely due to insolvency, forcing liquidation or a highly unfavorable restructuring.

Base CaseCentral scenario

The company continues to operate under severe capital constraints, relying on highly dilutive equity issuances to fund minimal operations. The co-development agreement with Adbiotech progresses slowly due to funding limitations, and Nasdaq compliance remains a persistent threat, keeping the stock under heavy selling pressure.

Bull CaseUpside scenario

Positive Phase 2 data for Burixafor (GPC-100) in multiple myeloma demonstrates strong CD34+ cell mobilization, providing a solid foundation for Phase 3 trials and pipeline expansion into sickle cell disease (SCD) and acute myeloid leukemia (AML). Additionally, the low leverage profile provides some flexibility to raise capital or secure strategic partnerships.

Scenarios reflect our research view at the research date.

Key Investment Merits

Burixafor (GPC-100) demonstrated strong Phase 2 efficacy, achieving successful stem cell mobilization in 89.5% of multiple myeloma patients with a same-day administration advantage over existing treatments.
The April 2026 co-development agreement with Adbiotech leverages external preclinical expertise to expand Burixafor's indications into SCD, AML, and solid tumors, potentially reducing early-stage R&D costs.

Key Investment Risks

Severe liquidity stress with only $2.6 million in cash as of March 31, 2026, and an ongoing quarterly cash burn rate that threatens near-term survival.
Nasdaq non-compliance regarding the minimum stockholders' equity requirement of $2.5 million, creating a high risk of delisting.
Zero commercial revenue and a long, capital-intensive path to potential commercialization for its clinical assets.
Significant historical management turnover and corporate restructuring, introducing high execution and governance risks.

Thesis Invalidation Triggers

Execution of a major, fully-funded strategic partnership or acquisition of Exicure by a larger biopharmaceutical firm.
An unexpected large-scale non-dilutive capital injection or grant that resolves the going concern status without diluting existing shareholders.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.